Skip to main content
SpringerLink
Log in

Variability of the anticoagulant effect according to body weight in patients treated with direct oral anticoagulants

  • CE-Research Letter to the Editor
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 42(5):373–498

    Article  PubMed  Google Scholar 

  2. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG et al (2021) 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612–1676

    Article  PubMed  Google Scholar 

  3. Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64(11):1128–1139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Salmonson T, Dogne JM, Janssen H, Garcia Burgos J, Blake P (2017) Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother 3(1):42–47

    Article  PubMed  Google Scholar 

  5. Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58(10):1265–1279

    Article  PubMed  PubMed Central  Google Scholar 

  6. Renda G, De Caterina R (2013) The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 59(3–4):53–62

    Article  CAS  PubMed  Google Scholar 

  7. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76(6):908–916

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14(6):1308–1313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):675–686

    Article  CAS  PubMed  Google Scholar 

  10. Peterson ED, Ashton V, Chen YW, Wu B, Spyropoulos AC (2019) Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J 212:113–119

    Article  CAS  PubMed  Google Scholar 

  11. Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M et al (2019) Efficacy and safety of Apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation 139(20):2292–2300

    Article  CAS  PubMed  Google Scholar 

  12. Patti G, Pecen L, Manu MC, Huber K, Rohla M, Renda G et al (2020) Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. Int J Cardiol 318:67–73

    Article  PubMed  Google Scholar 

  13. Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Li X et al (2020) Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: Insights from the Aristophanes Study. J Clin Med 9(6):1633

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U (2000) Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278(5):F817–F822

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Renzetti Hospital, Lanciano, Italy

    Lorenzo Belli & Francesco Radico

  2. Department of Clinical Pathology, Renzetti Hospital, Lanciano, Italy

    Raffaella Auciello

  3. University of Eastern Piedmont, Novara, Italy

    Giuseppe Patti

  4. Department of Neuroscience, Imaging and Clinical Sciences, G. d’Annunzio University of Chieti-Pescara, Chieti, Italy

    Sabina Gallina & Giulia Renda

  5. Department of Cardiology, SS. Annunziata Hospital, Chieti, Italy

    Sabina Gallina & Giulia Renda

Authors
  1. Lorenzo Belli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Radico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaella Auciello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Patti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabina Gallina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giulia Renda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulia Renda.

Ethics declarations

Human and animal rights

The study protocol was approved by the institutional Ethical Committee and was conducted in accordance with the principles of the Declaration of Helsinki.

Informed consent

Written informed consent was obtained from each patient.

Conflict of interest

L.B, F.R, R.A: None. G.P: speaker/consultant/advisory board fee from Abbott, Astra Zeneca, Sanofi, Amgen, Menarini, Bayer, Pfizer, BMS, Daiichi Sankyo, Chiesi, MSD, Boehringer Ingelheim, Servier, Guidotti, Medtronic, Biosensors, Terumo. S.G: None. G.R: speaker/consultant/advisory board fee from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, BMS/Pfizer, Menarini.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Belli, L., Radico, F., Auciello, R. et al. Variability of the anticoagulant effect according to body weight in patients treated with direct oral anticoagulants. Intern Emerg Med (2024). https://doi.org/10.1007/s11739-024-03553-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11739-024-03553-3

Search

Navigation